IO Biotech Inc reports results for the quarter ended June 30 - Earnings Summary
14/08/2025 22:05
IO Biotech Inc IOBT.OQ reported a quarterly adjusted loss of 35 cents per share for the quarter ended June 30, lower than the same quarter last year, when the company reported EPS of -31 cents. The mean expectation of five analysts for the quarter was for a loss of 36 cents per share. Wall Street expected results to range from -38 cents to -30 cents per share. Reported revenue was zero; analysts expected zero. IO Biotech Inc's reported EPS for the quarter was a loss of 40 cents. The company reported a quarterly loss of $26.22 million. IO Biotech Inc shares had fallen by 5.8% this quarter and gained 42.4% so far this year. FORECAST CHANGES The mean earnings estimate of analysts was unchanged in the last three months. In the last 30 days, there have been no earnings estimate revisions by analysts covering the company. RECOMMENDATIONS The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy," no "hold" and 1 "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is also "buy" Wall Street's median 12-month price target for IO Biotech Inc is $9.00, about 85.4% above its last closing price of $1.31 This summary was machine generated from LSEG data August 14 at 09:05 p.m. UTC. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
| QUARTER ENDING | ESTIMATE | ACTUAL | BEAT, MET, MISSED |
| Jun. 30 2025 | -0.36 | -0.35 | Beat |
| Mar. 31 2025 | -0.38 | -0.34 | Beat |
| Dec. 31 2024 | -0.39 | -0.48 | Missed |
| Sep. 30 2024 | -0.29 | -0.36 | Missed |